Technology | April 08, 2008

Mediware Medication Management Software Features Safety Upgrades

The newest version of Mediware's medication management software suite reportedly offers enhanced data integration and functional improvements for tracking of medication orders, administrations and histories.

Version 3.0 is said to provide functional improvements to each application in order to streamline communication between clinicians throughout the hospital. It also includes integration points designed to ease collaboration with other systems within the client�s environment.

Specific product enhancements for the suite include updated safe medication practices information to meet JCAHO inpatient safety standards, improved medication profiles and clinical information, increased alerts and notifications and upgraded screens and displays.

Mediware's suite combines the company's MediREC, WORx, MediMA and MediCOE applications. MediREC includes automated medication reconciliation that electronically captures home medications and provides longitudinal medication records to support reconciliation throughout a patient's stay. WORx is a pharmacy management solution for inpatient and outpatient settings, including inventory management, online adjudication and Web-based access for remote users. MediMAR includes bedside administration and documentation tools designed to ensure the correct medications are delivered to the right patient at the right time. MediCOE�s electronic clinician ordering streamlines orders associated with poor handwriting or patient misidentification.

April 2003

Related Content

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Overlay Init